drugset
Drugs / 68GaNOTA-Anti-HER2 VHH1
last change Oct 2025 re-read 3 minutes ago

68GaNOTA-Anti-HER2 VHH1

Diagnostic / imaging agent

Investigated by
University Hospital Brussels · Agentschap voor Innovatie door Wetenschap en Technologie, Project Toegepast Biomedisch onderzoek met een primair Maatschappelijke finaliteit. · Kom Op Tegen Kanker

Trials 2

today NCT03924466 · Ph 2 NCT03331601 · Ph 2
2018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT03924466 Apr 2019 → Nov 2024 cholangiocarcinoma, colorectal cancer, endometrial cancer, gastric cancer +6 University Hospital Brussels Unknown No outcome recorded
Phase 2 NCT03331601 Oct 2017 → Oct 2025 carcinoma University Hospital Brussels Terminated No outcome recorded Stop: Enrollment

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as 68GaNOTA-Anti-HER2 VHH1 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03331601 ↗
1

NCT03924466 ↗
Modality Diagnostic / imaging agent “the radiopharmaceutical 68-GaNOTA-Anti-HER2 VHH1 in brain metastasis using PET/CT imaging” NCT03331601 ↗
Route Intravenous “patients will be injected intravenously with 37 - 185 MBq 68GaNOTA-Anti-HER2 VHH1” NCT03924466 ↗